Kinetic fingerprint of antibody therapies predicts outcomes of Alzheimer clinical trials
Linse, S.; Scheidt, T.; Bernfur, K.; Vendruscolo, M.; Dobson, C. M.; Cohen, S. I.; Sileikis, E.; Lundquist, M.; Qian, F.; O'Malley, T.; Bussiere, T.; Weinreb, P. H.; Xu, C. K.; Meisl, G.; Devenish, S.; Knowles, T. P.; Hansson, O.
Show abstract
The amyloid cascade hypothesis, according to which the self-assembly of amyloid-{beta} peptide (A{beta}) is a causative process in Alzheimers disease, has driven many therapeutic efforts for the past 20 years. Failures of clinical trials investigating A{beta}-targeted therapies have been interpreted as evidence against this hypothesis, irrespective of the characteristics and mechanisms of action of the therapeutic agents, which are highly challenging to assess. We bring together kinetic analysis with quantitative binding measurements to address the mechanisms of action of four clinical stage anti-A{beta} antibodies, aducanumab, gantenerumab, bapineuzumab and solanezumab. We reveal and quantify the striking differences of these antibodies on the aggregation kinetics and on the production of oligomeric aggregates, and link these effects to the affinity and stoichiometry of each antibody for monomeric and fibrillar forms of A{beta}. Our results uncover that, uniquely amongst these four antibodies, aducanumab dramatically reduces the flux of oligomeric forms of A{beta}.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology 94%
- Endo-lysosomal Aβ concentration and pH enable formation of Aβ oligomers that potently induce Tau missorting 94%
- Opposing roles of physiological and pathological amyloid-β on synapses in live human brain slice cultures 94%
Similar papers in this journal
Similar papers in this journal
- Twelve phosphomimetic mutations induce the assembly of recombinant full-length human tau into paired helical filaments 93%
- Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models 93%
- Cystatin F (Cst7) drives sex-dependent changes in microglia in an amyloid-driven model of Alzheimer's Disease 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.